Corona Remedies

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE02ZQ01018
  • NSEID: CORONA
  • BSEID: 544644
INR
1,728.40
47.65 (2.84%)
BSENSE

Jun 12, 03:30 PM

BSE+NSE Vol: 8.91 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

8.91 k (-66.84%) Volume

Shareholding (Mar 2026)

FII

2.25%

Held by 21 FIIs

DII

7.02%

Held by 9 DIIs

Promoter

69.00%

Why is Corona Remedies Ltd falling/rising?

12-Jun-2026

As of 11-Jun, the stock price of Corona Remedies Ltd is currently at 1,680.75, reflecting a decline of 2.88%. Despite a year-to-date increase of 21.28%, recent trends show consecutive losses and negative performance relative to the market.

As of 11-Jun, the stock price of Corona Remedies Ltd is falling, currently at 1,680.75, which reflects a decrease of 49.85 or 2.88%. This decline is part of a broader trend, as the stock has underperformed the sector by 3.34% today and has experienced consecutive losses over the last two days, totaling a drop of 5.16% in that period. The stock also touched an intraday low of Rs 1656.6, marking a decrease of 4.28%.<BR><BR>In terms of performance relative to the market, the stock has shown a negative return of 1.25% over the past week and 4.13% over the past month, while the benchmark Sensex has declined by 0.71% and 2.87%, respectively. Despite a year-to-date increase of 21.28%, the recent trends indicate a weakening position.<BR><BR>While there are positive factors such as high management efficiency and a net-debt-free status, these have not been sufficient to counteract the recent price declines. Additionally, although institutional investor participation has increased, the current market sentiment appears to be negative, contributing to the stock's falling price.

View full answer

What does Corona Remedies do?

11-Jun-2026

Corona Remedies Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 353 Cr and a net profit of 45 Cr for March 2026, with a market cap of INR 10,856 Cr. Key metrics include a P/E ratio of 53.00 and a return on equity of 26.75%.

Overview:<BR>Corona Remedies Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History:<BR>The specific incorporation year and any status changes are not provided. The latest quarterly results reported are for March 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Net Sales: 353 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 45 Cr (Quarterly Results - Mar 2026) <BR>Market-cap: INR 10,856 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 53.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.16 <BR>Return on Equity: 26.75% <BR>Price to Book: 14.50 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: Not available. <BR>Email: Not available. <BR>Website: Not available.

View full answer

How big is Corona Remedies?

11-Jun-2026

As of 10th June, Corona Remedies Ltd has a market capitalization of 10,856.00 Cr, with recent net sales of 1,403.18 Cr and a net profit of 185.12 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Corona Remedies Ltd has a market capitalization of 10,856.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1,403.18 Cr, while the sum of Net Profit for the same period is 185.12 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds are valued at 606.34 Cr, and Total Assets amount to 929.86 Cr.

View full answer

Who are the peers of the Corona Remedies?

11-Jun-2026

Corona Remedies' peers include Alivus Life, Marksans Pharma, Shilpa Medicare, Viyash Scientifi, Sanofi Consumer, P & G Health Ltd, Akums Drugs, Strides Pharma, and Blue Jet Health. Most peers show Below Average growth and management risk, with Shilpa Medicare having the highest 1-year return at 15.43%, while Blue Jet Health has the lowest at -47.29%.

Peers: The peers of Corona Remedies are Alivus Life, Marksans Pharma, Shilpa Medicare, Viyash Scientifi, Sanofi Consumer, P & G Health Ltd, Akums Drugs, Strides Pharma, Blue Jet Health.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sanofi Consumer and P & G Health Ltd, while Good management risk is found at Alivus Life, Marksans Pharma, and Blue Jet Health, and Average management risk is noted for Viyash Scientifi and Akums Drugs. Below Average management risk is present at Shilpa Medicare and Strides Pharma. All peers exhibit Below Average growth, except for Akums Drugs, which has Good growth. Capital Structure ratings show Excellent at Alivus Life, Marksans Pharma, Sanofi Consumer, P & G Health Ltd, and Blue Jet Health, while Good is observed at Akums Drugs, and Below Average at Shilpa Medicare, Viyash Scientifi, and Strides Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Shilpa Medicare at 15.43%, while Blue Jet Health has the lowest at -47.29%. Corona Remedies' 1-year return is not available for comparison. Additionally, Blue Jet Health is the only peer with a negative six-month return.

View full answer

Should I buy, sell or hold Corona Remedies Ltd?

10-Jun-2026

Has Corona Remedies Ltd declared dividend?

13-May-2026

Yes, Corona Remedies Ltd has declared a 100% dividend with an ex-date of June 19, 2026. However, the dividend yield is 0%, and total returns have been mixed, with a 7.52% return in the last 3 months but no returns over longer periods.

Corona Remedies Ltd has declared a 100% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Ex-date: 19 Jun 26<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was 7.52%, the dividend return was 0%, resulting in a total return of 7.52%.<BR><BR>Over the last 6 months, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>For the 1-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the last 2 years, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>For the 3-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the last 4 years, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>Over the last 5 years, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>Overall, while Corona Remedies Ltd has declared a dividend, the dividend yield remains at 0%, indicating that there has been no effective return from dividends in recent years. The total returns over various periods show a mixed performance, with a notable return in the last 3 months but no returns in the longer periods.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

High Management Efficiency with a high ROCE of 0%

 
2

The company is Net-Debt Free

 
3

Healthy long term growth as Operating profit has grown by an annual rate 0%

 
4

Flat results in Mar 26

5

With ROCE of 29.5, it has a Very Expensive valuation with a 12.4 Enterprise value to Capital Employed

6

Increasing Participation by Institutional Investors

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 10,454 Cr (Small Cap)

stock-summary
P/E

53.00

stock-summary
Industry P/E

34

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.16

stock-summary
Return on Equity

26.75%

stock-summary
Price to Book

13.77

Revenue and Profits:
Net Sales:
353 Cr
(Quarterly Results - Mar 2026)
Net Profit:
45 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
8.67%
0.65%
9.32%
6 Months
0%
0.70%
0.7%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Corona Remedies for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Announcements stock-summary

Announcement under Regulation 30 (LODR)-Newspaper Publication

10-Jun-2026 | Source : BSE

Newspaper Publication - Intimation of 22nd Annual General Meeting of the Company through Video Conferencing / Other Audio Visual Means (VC / OAVM) facility

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

10-Jun-2026 | Source : BSE

Intimation for Schedule of Analysts / Investor Conference

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

03-Jun-2026 | Source : BSE

Intimation for Non-Deal Roadshow

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Corona Remedies Ltd has declared 100% dividend, ex-date: 19 Jun 26

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
0
EBIT to Interest (avg)
27.90
Debt to EBITDA (avg)
0.56
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.54
Tax Ratio
23.03%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
9.26%
ROCE (avg)
29.49%
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
53
Industry P/E
34
Price to Book Value
14.19
EV to EBIT
41.90
EV to EBITDA
36.49
EV to Capital Employed
12.36
EV to Sales
7.63
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
29.49%
ROE (Latest)
26.75%

Technicals key factors

Indicator
Weekly
Monthly
MACD
RSI
No Signal
Bollinger Bands
Bullish
KST
Dow Theory
Mildly Bearish
OBV
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 17 Schemes (6.35%)

FIIs

Held by 21 FIIs (2.25%)

Promoter with highest holding

Ankurbhai K Mehta (22.0%)

Highest Public shareholder

Sepia Investments Limited (19.76%)

Individual Investors Holdings

0.77%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 3.12% vs -5.18% in Dec 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 9.21% vs -20.90% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "353.09",
          "val2": "342.42",
          "chgp": "3.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "62.02",
          "val2": "83.16",
          "chgp": "-25.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.38",
          "val2": "1.66",
          "chgp": "-16.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-19.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "45.05",
          "val2": "41.25",
          "chgp": "9.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "17.56%",
          "val2": "24.29%",
          "chgp": "-6.73%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "707.67",
          "val2": "605.04",
          "chgp": "16.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "148.25",
          "val2": "116.34",
          "chgp": "27.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.92",
          "val2": "6.02",
          "chgp": "-34.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "98.55",
          "val2": "72.93",
          "chgp": "35.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "20.95%",
          "val2": "19.23%",
          "chgp": "1.72%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,050.09",
          "val2": "902.73",
          "chgp": "16.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "231.41",
          "val2": "185.76",
          "chgp": "24.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "5.58",
          "val2": "8.41",
          "chgp": "-33.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-19.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "139.80",
          "val2": "117.70",
          "chgp": "18.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "22.04%",
          "val2": "20.58%",
          "chgp": "1.46%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,403.18",
          "val2": "1,196.42",
          "chgp": "17.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "293.44",
          "val2": "239.98",
          "chgp": "22.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "6.97",
          "val2": "10.60",
          "chgp": "-34.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-19.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "184.85",
          "val2": "149.05",
          "chgp": "24.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "20.91%",
          "val2": "20.06%",
          "chgp": "0.85%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Mar'26 - QoQstock-summary

Mar'26
Dec'25
Change(%)
Net Sales
353.09
342.42
3.12%
Operating Profit (PBDIT) excl Other Income
62.02
83.16
-25.42%
Interest
1.38
1.66
-16.87%
Exceptional Items
0.00
-19.10
100.00%
Standalone Net Profit
45.05
41.25
9.21%
Operating Profit Margin (Excl OI)
17.56%
24.29%
-6.73%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2026 is 3.12% vs -5.18% in Dec 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is 9.21% vs -20.90% in Dec 2025

Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
707.67
605.04
16.96%
Operating Profit (PBDIT) excl Other Income
148.25
116.34
27.43%
Interest
3.92
6.02
-34.88%
Exceptional Items
0.00
0.00
Standalone Net Profit
98.55
72.93
35.13%
Operating Profit Margin (Excl OI)
20.95%
19.23%
1.72%
Values in Rs Cr.
Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

Nine Monthly Results Snapshot (Standalone) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
1,050.09
902.73
16.32%
Operating Profit (PBDIT) excl Other Income
231.41
185.76
24.57%
Interest
5.58
8.41
-33.65%
Exceptional Items
-19.10
0.00
Standalone Net Profit
139.80
117.70
18.78%
Operating Profit Margin (Excl OI)
22.04%
20.58%
1.46%
Values in Rs Cr.
Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

Annual Results Snapshot (Standalone) - Mar'26stock-summary

Mar'26
Mar'25
Change(%)
Net Sales
1,403.18
1,196.42
17.28%
Operating Profit (PBDIT) excl Other Income
293.44
239.98
22.28%
Interest
6.97
10.60
-34.25%
Exceptional Items
-19.10
0.00
Standalone Net Profit
184.85
149.05
24.02%
Operating Profit Margin (Excl OI)
20.91%
20.06%
0.85%
Values in Rs Cr.
Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

stock-summaryCompany CV
About Corona Remedies Ltd stock-summary
stock-summary
Corona Remedies Ltd
Small Cap
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available